{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:16:27Z","timestamp":1788250587579,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.biopha.2024.116655","type":"journal-article","created":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:10:34Z","timestamp":1714176634000},"page":"116655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["A novel dosing approach for rituximab in glomerular diseases based on a population pharmacokinetic analysis"],"prefix":"10.1016","volume":"175","author":[{"given":"Jan Miroslav","family":"Hartinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6541-738X","authenticated-orcid":false,"given":"Martin","family":"\u0160\u00edma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenka","family":"Hru\u0161kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3022-1413","authenticated-orcid":false,"given":"Alena","family":"Pilkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vojt\u011bch","family":"Kr\u00e1tk\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4162-128X","authenticated-orcid":false,"given":"Romana","family":"Ry\u0161av\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Jan\u010dov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Bobek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Dou\u0161a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Francov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladim\u00edr","family":"Tesa\u0159","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ond\u0159ej","family":"Slana\u0159","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.116655_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1024068","article-title":"Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives","volume":"13","author":"Hartinger","year":"2022","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.biopha.2024.116655_bib2","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2215\/CJN.01070118","article-title":"Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis","volume":"13","author":"Gomez Mendez","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116655_bib3","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/art.20858","article-title":"Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial","volume":"52","author":"Sfikakis","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.biopha.2024.116655_bib4","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: A 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.biopha.2024.116655_bib5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40262-019-00826-5","article-title":"Non-linear rituximab pharmacokinetics and complex relationship between rituximab concentrations and anti-neutrophil cytoplasmic antibodies (ANCA) in ANCA-associated vasculitis: The RAVE trial revisited","volume":"59","author":"Bensalem","year":"2020","journal-title":"Clin. Pharm."},{"issue":"9","key":"10.1016\/j.biopha.2024.116655_bib6","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1177\/0091270007305297","article-title":"Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response","volume":"47","author":"Breedveld","year":"2007","journal-title":"J. Clin. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2024.116655_bib7","doi-asserted-by":"crossref","first-page":"826","DOI":"10.4161\/mabs.26008","article-title":"Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics","volume":"5","author":"Golay","year":"2013","journal-title":"MAbs"},{"issue":"6","key":"10.1016\/j.biopha.2024.116655_bib8","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1365-3083.2000.00745.x","article-title":"Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms","volume":"51","author":"Harjunp\u00e4\u00e4","year":"2000","journal-title":"Scand. J. Immunol."},{"issue":"9","key":"10.1016\/j.biopha.2024.116655_bib9","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood.V98.9.2771","article-title":"Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species","volume":"98","author":"Bellosillo","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.biopha.2024.116655_bib10","first-page":"357","article-title":"Rituximab exhibits altered pharmacokinetics in patients with membranous nephropathy","volume":"53","author":"Fogueri","year":"2019","journal-title":"Ann. Pharm."},{"issue":"9950","key":"10.1016\/j.biopha.2024.116655_bib11","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.biopha.2024.116655_bib12","doi-asserted-by":"crossref","first-page":"826","DOI":"10.4161\/mabs.26008","article-title":"Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics","volume":"5","author":"Golay","year":"2013","journal-title":"mAbs"},{"issue":"5","key":"10.1016\/j.biopha.2024.116655_bib13","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/bcp.12098","article-title":"Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease","volume":"76","author":"Puisset","year":"2013","journal-title":"Br. J. Clin. Pharm."},{"issue":"12","key":"10.1016\/j.biopha.2024.116655_bib14","doi-asserted-by":"crossref","first-page":"938","DOI":"10.2174\/1389200221666200719004035","article-title":"The influence of different disease states on rituximab pharmacokinetics","volume":"21","author":"Wang","year":"2020","journal-title":"Curr. Drug Metab."},{"issue":"11","key":"10.1016\/j.biopha.2024.116655_bib15","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1136\/archdischild-2020-321211","article-title":"Use of rituximab in paediatric nephrology","volume":"106","author":"Sinha","year":"2021","journal-title":"Arch. Dis. Child"},{"issue":"9","key":"10.1016\/j.biopha.2024.116655_bib16","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1177\/0091270007305297","article-title":"Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response","volume":"47","author":"Breedveld","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2024.116655_bib17","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jim.2017.09.001","article-title":"Detection and quantification of rituximab in the human urine","volume":"451","author":"Jacobs","year":"2017","journal-title":"J. Immunol. Methods"},{"issue":"5","key":"10.1016\/j.biopha.2024.116655_bib18","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/bcp.12662","article-title":"Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia","volume":"80","author":"Assouline","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116655_bib19","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","article-title":"Immunogenicity to therapeutic proteins: impact on PK\/PD and efficacy","volume":"14","author":"Chirmule","year":"2012","journal-title":"AAPS\u00a0J."},{"issue":"14","key":"10.1016\/j.biopha.2024.116655_bib20","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2011-09-380949","article-title":"The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL","volume":"119","author":"M\u00fcller","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2024.116655_bib21","article-title":"Population pharmacokinetics of rituximab in pediatric patients with frequent-relapsing or steroid-dependent nephrotic syndrome","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharm."},{"issue":"9","key":"10.1016\/j.biopha.2024.116655_bib22","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"issue":"4","key":"10.1016\/j.biopha.2024.116655_bib23","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/rheumatology\/kex484","article-title":"Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis","volume":"57","author":"Cornec","year":"2018","journal-title":"Rheumatol. (Oxf.)"},{"key":"10.1016\/j.biopha.2024.116655_bib24","article-title":"Tolerance and safety of rapid 2-hour infusion of rituximab in patients with kidney-affecting autoimmune diseases and glomerulonephritides: a single-centre experience","author":"Hartinger","year":"2018","journal-title":"Eur. J. Hosp. Pharm."},{"issue":"3069","key":"10.1016\/j.biopha.2024.116655_bib25","article-title":"Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab","volume":"10","author":"Boyer-Suavet","year":"2020","journal-title":"Front. Immunol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224005390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224005390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T14:36:19Z","timestamp":1741012579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224005390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":25,"alternative-id":["S0753332224005390"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116655","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel dosing approach for rituximab in glomerular diseases based on a population pharmacokinetic analysis","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116655","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116655"}}